Chronic Myeloid Leukemia (CML) Treatment Market Size, Share, Growth ,Analysis 2024-2033

"The new report published by The Business Research Company, titled Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $7.73 billion in 2023 to $8.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12084&type=smp

Rising Incidence Of Chronic Myeloid Leukemia (CML)
The rising incidence and prevalence of chronic myeloid leukemia (CML) population is expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Chronic myeloid leukemia also known as chronic myelogenous leukemia, is a type of cancer that affects the bone marrow and blood. It is characterized by the overproduction of immature white blood cells called myeloid cells. Chronic myeloid leukemia (CML) treatment helps to slow the progression of cancer and stop it from reaching an advanced phase. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the rising incidence and prevalence of chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment market going forward.

Innovation In Drug Development For Better Treatment
Product Innovation is a key trend gaining popularity in the chronic myeloid leukemia (CML) treatment market. Companies operating in the chronic myeloid leukemia (CML) treatment market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Novartis, a Switzerland-based multinational pharmaceutical corporation, announced FDA (Foods and Drugs Association) approval of Scemblix (asciminib) for the treatment of chronic myeloid leukemia. Scemblix is the first FDA-approved CML treatment. Scemblix works by binding to the ABL myristoyl pocket and is used to treat patients who experience resistance and, or intolerance to currently available TKI therapies1-3. At 24 weeks, Scemblix outperformed Bosulif (bosutinib) in terms of major molecular response (MMR) rate (25% vs. 13%) and more than three times lower discontinuation rates due to adverse effects (7% vs. 25%).

The chronic myeloid leukemia (cml) treatment market covered in this report is segmented -

1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types
3) By Application: Hospitals, Clinic, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12084&type=discount

Major companies operating in the chronic myeloid leukemia (cml) treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, Bio-Path Holdings Inc.

Contents of the report:
1. Executive Summary
2. Chronic Myeloid Leukemia (CML) Treatment Market Report Structure
3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies
4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario
5. Chronic Myeloid Leukemia (CML) Treatment Market Size And Growth
…..
27. Chronic Myeloid Leukemia (CML) Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.